JAK2 and leukemia: Pharmacologic inhibition of JAK2 has been shown to suppress STAT1/STAT3-driven cytokine responses, reduce Th1/Th17 polarization, and preserve Treg stability, while maintaining graft-versus-leukemia (GvL) effects in preclinical models [7,8,9,10].